Plasma serine protease inhibitor (SERPINA5), a molecule we find at elevated levels in IPF relative to control patients, has been shown to be upregulated in the intra-alveolar space of patients with interstitial lung diseases (IPF included), and is involved in the inhibition of fibrinolysis, especially in IPF53. The gene discussed is SERPINA5; the disease is interstitial lung disease.